Active, not recruitingPhase 3NCT06015737

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Anifrolumab(combination_product)
Enrollment: 306 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2024 – 2027

Study locations (30)

Research Site, Glendale, Arizona, United States
Research Site, Phoenix, Arizona, United States
Research Site, Covina, California, United States
Research Site, Fountain Valley, California, United States
Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, Orange, California, United States
Research Site, San Francisco, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Denver, Colorado, United States
Research Site, New Haven, Connecticut, United States
Research Site, Washington D.C., District of Columbia, United States
Research Site, Fort Lauderdale, Florida, United States
Research Site, Miami, Florida, United States
Research Site, Plantation, Florida, United States
+15 more locations on ClinicalTrials.gov

Collaborators

Parexel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06015737 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus →

← Back to all trials